ENovate Biolife announces start of Clinical Study for Rhinitis

For Immediate Release

California, July 20, 2011: ENovate Biolife, a specialty healthcare company, announced today that it has initiated a Phase IIa clinical trial with its lead product E-RH-06 in subjects with Rhinitis. ENovate Biolife has received ethics committee approval for safety and dose determining study for investigational product E-RH-06 for the metabolic management of chronic or recurrent, non-infective nasal congestion with-or-without rhinorrhea.
Rhinitis (allergic or non allergic) is a clinical problem recognized worldwide and detrimentally affects approximately 40 million people in the United States alone. Current available therapies focus on symptomatic relief and at the same time most of them have questionable abuse liability. This fact pointed to the need of development of a product which focused on the metabolic management of the disease as well as has a good safety profile. The company’s lead product E-RH-06 provides essential nutrients and phytoconstituents which helps to restore the normal homeostasis of metabolic processes that are associated with Rhinitis.
ENovate Biolife is already promoting the opportunity to western pharmaceutical and medical food companies in anticipation of the clinical data being available in Aug 2012.
In the ongoing randomized double dummy, double blind Phase IIa trial 2 different doses of E-RH-06 will be tested against placebo. Subjects suffering with persistent or recurrent nasal congestion and/ or rhinorrhea will be dosed for 12 weeks with a follow-up observation period of 4 weeks to assess the sustained effect of investigational product. The primary objective is to determine the safety and efficacy of the investigational product with secondary objective to determine the appropriate dose, onset of action and sustained efficacy.
“We are delighted that the development of our innovative product E-RH-06 has progressed to this stage and rapidly move this innovative approach through the development process, so that it can become available to the patients suffering from rhinitis of various etiology,” stated Jayesh Chaudhary, Director of ENovate Biolife.
About ENovate Biolife
ENovate Biolife is a Specialty Healthcare Company actively involved in Design and Development of Scientifically validated Dietary Supplements and Medical Foods. ENovate is part of a Multinational group with presence in US and Asia, having 2 decades of experience in the Healthcare industry. ENovate is committed to offer Innovative Science based products to support optimal health.

Contact us at
ENOVATE BIOLIFE LLC.
552, Shorebird Circle, Unit # 1101,
Redwood City,
CA 94065 USA
Tel: (650) 855-4832
URL: www.enovatebiolife.com
Email: bizdev@enovatebiolife.com

The company is focused on the pre-clinical and clinical development of novel therapeutics in the areas of Sexual Medicine, Pain & Inflammation, Metabolic disorders and Allergies. All our products address high unmet medical needs and commercially attractive markets.

203, Morya Landmark, Off New Link Road, Andheri (w), Mumbai - 400053

This release was published on openPR.